Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Chuikyo to Assess Cost-Effectiveness of 5 Listed Drugs, Industry Leery of Price Cuts
May 29, 2014
- Pharmaceuticals and Medical Devices Safety Information Calls for Proper Use of Schizophrenia Treatment Xeplion
May 29, 2014
- Integrated Guidelines Will Apply to “Research” Conducted by the Media as Well: MHLW
May 29, 2014
- J-ADNI Data Falsification “Unacceptable” If True: MHLW
May 28, 2014
- Approval for Remicade Biosimilar Products Reported to PAFSC’s Second Committee
May 28, 2014
- CRC Training Program Presented to Panel on Clinical Research Promotion
May 27, 2014
- Diet Enacts Japanese NIH-Related Bills
May 26, 2014
- MHLW to Discuss Setting Rules on OTC Switching of Diagnostics at Panel on In Vitro Diagnostics
May 23, 2014
- PAFSC’s First Committee to Review LEO Pharma’s Psoriasis Drug on May 30
May 22, 2014
- Collaborations with PMDA, Prefectures Crucial in PIC/S: MHLW
May 22, 2014
- Risk Management Plans for 8 APIs Published Since April 2013; Will Be Required for Approval of New Drugs and Biosimilars Starting October 1, 2014
May 22, 2014
- Kyowa Kirin Workers’ Clinical Study Misconduct “Utterly Unacceptable”: Minister
May 21, 2014
- MHLW, MOF, Cabinet Office to Come to Agreement on Once-yearly NHI Price Revision by End May
May 21, 2014
- Clinical Research Grants Might Fall Due to New JPMA Rule
May 20, 2014
- PIC/S Committee OKs Japan’s Accession from July 2014
May 20, 2014
- NCC, NCI of US Ink MOU on Joint Research, Academic Interchanges
May 20, 2014
- Chuikyo to Discuss Sharp Difference in NHI Prices of Identical Products Tenozet, Viread
May 16, 2014
- Government Says Xeplion Approval Reasonable
May 15, 2014
- Chuikyo OKs NHI Price Listing of SGLT-2 Inhibitors, New Point-Based Calculations Adopted from This Time
May 15, 2014
- MHLW to Report Two Remicade Biosimilars to PAFSC’s Second Committee on Drugs on May 26
May 15, 2014
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…